<DOC>
	<DOCNO>NCT01248988</DOCNO>
	<brief_summary>The purpose study collect safety information follow routine vaccination Synflorixâ„¢ among infant Korea .</brief_summary>
	<brief_title>Post Marketing Surveillance Synflorix Vaccine Safety Among Infants Korea</brief_title>
	<detailed_description>Rationale protocol amendment : The therapeutic indication Synflorix Korea update . The protocol amend reflect update .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representatives comply requirement protocol . Korean male female subject whose age receive first vaccination Synflorix 6 week 5 year . Written , sign thumbprinted informed consent obtain parent ( ) / Legally Acceptable Representative ( ) child . Where parent ( ) /Legally acceptable representative illiterate , consent form countersign witness . At time Post Marketing Surveillance entry , contraindication precaution use indicated local Prescribing Information check infant must include Post Marketing Surveillance contraindication . Any change locally approve Prescribing Information must implement immediately . Subjects receive investigational nonregistered pneumococcal vaccine 30 day prior study start enrol . Subjects previous administration pneumococcal vaccine Synforix enrol study . A male female child &gt; = 5 year age study entry .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Synflorix</keyword>
	<keyword>Pneumococcal disease</keyword>
</DOC>